일일 뉴스

Kangwon National University’s College of Pharmacy has been running Objective Structured Clinical Examinations (OSCE) for four years, providing students with hands‑on clinical counseling experience in simulated pharmacy and hospital settings.

Nationwide pharmacy student association DYK held a medication counseling campaign for seniors at Seoul Elderly Welfare Center, emphasizing safe drug use.

Migraine prevention is moving from reactive acute treatment to proactive CGRP‑targeted therapy, aiming to block attacks at the source and improve patient productivity.

ARKGEN BioScions announced a 10 billion KRW Series A round, raising total funding to 14 billion KRW to accelerate development of next‑generation multi‑antibody immuno‑oncology drugs.

The Pohang Pharmaceutical Society visited the Elim Faith House senior home, providing essential medicines and a joint choir‑guitar concert to uplift residents.

Seoul National University Hospital’s Rare Disease Center and the Korea Rare & Essential Medicines Center have signed an MOU to establish regular collaboration, aiming to provide faster information and treatment guidance for rare disease patients.

The Korean Health & Welfare Human Resources Institute announced a 10‑week, 68‑hour CEO training program for long‑term care policy leaders, running through October 2026.

Albozen Korea received the Social Contribution Company Award from Korea Economic Daily and the Ministry of Employment and Labor for its environmental, youth and vulnerable‑group programs.

The Korean Society of Sports Pharmacy hosted its inaugural 2026 regular academic conference, emphasizing the convergence of clinical research and data analytics for smart sports care.

The Korean Society of Clinical Pharmacy will hold a real‑time Zoom training on August 21, covering dyslipidemia, hypertension and type‑2 diabetes with a focus on the latest 2026 guidelines.

The Dongdaemun-gu Pharmacists Association hosted a 2026 training session for about 240 pharmacists, featuring practical workshops and a community‑fundraising campaign.

GSK ended its $2.2 bn collaboration with Alector after two sortilin‑targeting candidates, including latozinemab, failed in clinical trials.